🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSemaglutide and MASH — liver fat reduction quantification

Semaglutide and MASH — liver fat reduction quantification

MASHdoc_SA Mon, Jun 8, 2026 at 3:08 PM 13 replies 146 viewsPage 1 of 3
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jun 8, 2026 at 3:08 PM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I am trying to establish is how much of the between-person variation is pharmacokinetic and how much is just adherence measured badly. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
3 23TirzTom, TrialTracker_MD, JennaRN
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Jun 8, 2026 at 3:14 PM#2
MASHdoc_SA said:
The dose-response is real but shallow at the top.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Correct me if the detail matters more than I have assumed.

Last edited: Jun 8, 2026 at 5:14 PM
2 22KristenIndy, MarkLI_maint
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jun 8, 2026 at 3:21 PM#3
MASHdoc_SA said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: Jun 8, 2026 at 7:21 PM
1 21TomTeleRx
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Jun 8, 2026 at 3:27 PM#4

This one has a reasonably settled answer, so here it is. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Last edited: Jun 8, 2026 at 8:27 PM
50 20AussieAnna, BethLabQueen, ChrisMacros and 47 others
Reply Quote Save Share Report
wanda_boise
Member
412
1,890
Aug 2024
Boise, ID
Jun 8, 2026 at 4:06 PM#5
VendorMark said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

49 19ben_calgary, patPC_UT, Dr.DermMIA and 46 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
MASH resolution without worsening fibrosis — endpoint analysis11 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register